

WEST Search History

DATE: Wednesday, November 05, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT; PLUR=YES; OP=ADJ</i>			
L5	l1 and L4	17	L5
L4	l2 or l3	32	L4
L3	cad-11 or cad11	3	L3
L2	cadherin-11	29	L2
L1	antisense or anti-sense	20349	L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1805SXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced

NEWS EXPRESS OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:17:59 ON 05 NOV 2003

=> file medline caplus biotechno scisearch biosis embase
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 09:18:41 ON 05 NOV 2003

FILE 'CAPLUS' ENTERED AT 09:18:41 ON 05 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 09:18:41 ON 05 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 09:18:41 ON 05 NOV 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'BIOSIS' ENTERED AT 09:18:41 ON 05 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:18:41 ON 05 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

=> s cadherin-11
L1 400 CADHERIN-11

=> antisense or anti-sense
ANTISENSE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s antisense or anti-sense
L2 129686 ANTISENSE OR ANTI-SENSE

=> s l1 and l2
L3 13 L1 AND L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 5 DUP REM L3 (8 DUPLICATES REMOVED)

=> d ti 1-5

L4 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
TI **Cadherin-11** modulates the terminal differentiation and
fusion of human trophoblastic cells in vitro.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
TI Nucleic acid compositions, kits, and methods for identification,
assessment, prevention, and therapy of human breast cancer

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
TI Methods and compositions for treatment of inflammatory joint disease using
cadherin-11 modulating agents

L4 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 2
TI In fibroblasts Vegf-D expression is induced by cell-cell contact mediated
by **cadherin-11**.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
TI **Cadherin-11** expression and an assay and treatment for
cellular invasiveness

=> d ab 1-5

L4 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
AB E-cadherin and **cadherin-11** are two members of the
cadherin gene family of cell adhesion molecules that are differentially

expressed during the aggregation, differentiation, and fusion of trophoblasts isolated from the human term placenta. E-cadherin expression is highest in cytotrophoblasts and decreases as these mononucleate cells undergo terminal differentiation and fusion. In contrast, **cadherin-11** expression increases during the formation of multinucleated syncytium in these primary cultures. To define the role(s) of **cadherin-11** in this developmental process, we examined the effects of ectopic **cadherin-11** expression on the differentiation and fusion of JEG-3 choriocarcinoma cells, a mononucleate trophoblastic cell line. **Cadherin-11** expression, but not the ectopic expression of the related cadherin subtype, cadherin-6, resulted in the formation of multinucleated syncytium in the transfected JEG-3 cell cultures. Multinucleated syncytium formation in the JEG-3 cells transfected with **cadherin-11** was associated with a reduction in E-cadherin, alpha-, beta-, gamma-catenin, and p120(ctn) expression. **Cadherin-11** also reduced cell proliferation and increased the levels of the mRNA transcript encoding the beta subunit of human chorionic gonadotropin, a biochemical marker of trophoblast differentiation, in these cultures. Furthermore, primary cytotrophoblasts cultured in the presence of **antisense** oligonucleotides specific for **cadherin-11** maintained E-cadherin expression and did not undergo terminal differentiation and fusion with time in culture. Collectively, these observations demonstrate that **cadherin-11** contributes to the morphological and functional differentiation of cultured mononucleate trophoblastic cells in a highly specific manner.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AB The invention relates to nucleic acid marker compns., kits and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the nucleic acid markers is correlated with the presence of breast cancer. The level of expression of numerous potential markers was measured in cells obtained from breast cancer tissue samples obtained from fifteen patients afflicted with breast cancer and from eleven breast cancer cell cultures, based on comparison with expression levels of each marker in corresponding non-cancerous breast tissue and cell cultures. The 15 cancer tissue samples include (i) five invasive lobular carcinomas (ILC), (ii) five invasive ductal carcinomas (IDC), and (iii) five samples of ductal carcinoma in situ (DCIS). As an addnl. evaluation of ability to indicate breast cancer, individual markers that were identified by transcriptional profiling criteria were also tested in six different subtracted library expts. In addn., protein profiling expts. were undertaken to assess whether the proteins assocd. with the expression of individual markers of the invention are secreted. Table 21 lists approx. 43,500 GenBank Accession Nos. from the present invention. [This abstr. record is one of 8 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AB A method is provided for treating inflammatory joint diseases by inhibiting **cadherin-11**-mediated cellular function using a **cadherin-11** modulating agent. Also provided are screening assays for identifying pharmaceutical lead compds. capable of modulating cellular functions of **cadherin-11**, e.g. cell proliferation, apoptosis, factor secretion, and binding of **cadherin-11** to **cadherin-11** counter-receptor, inhibiting binding of **cadherin-11** to its counter-receptor either in the context of a cell or in sol. form.

L4 ANSWER 4 OF 5 MEDLINE on STN

DUPLICATE 2

AB Vascular endothelial growth factors (VEGFs) are a highly conserved family of growth factors all angiogenic in vivo with mitogenic and chemotactic

activity on endothelial cells. VEGFs are expressed in fibroblasts either in hypoxia or in response to growth factors. Here we report that, differently from the other members of the family, Vegf-D is induced by cell-cell contact. By in situ hybridization we demonstrated that noninteracting fibroblasts express low levels of Vegf-D mRNA, whereas contacting cells express high levels of Vegf-D transcripts. By immunostaining we observed that the surface protein **cadherin-11** is localized at the opposite sites of interacting cell surfaces. Ca(2+) deprivation from the culture medium determined the loss of **cadherin-11** from the cell surfaces and down-regulation of Vegf-D mRNA. Moreover, a **cadherin-11 antisense** RNA construct inhibited Vegf-D expression in confluent BALB/c fibroblasts, whereas in NIH 3T3 cells, which express low levels of **cadherin-11**, Vegf-D induction could be obtained by overexpression of **cadherin-11**. This suggests that cell interaction mediated by **cadherin-11** induces the expression of the angiogenic factor Vegf-D in fibroblasts.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AB A method of modulating differentiation or neoplastic transformation of cells is provided in which the cells are caused to increase or decrease cad-11 expression or function. The method has application in affecting differentiation or neoplastic transformation of cells, preventing or terminating pregnancy by altering cad-11 function or expression in trophoblast cells, or for reducing the viability of carcinoma cells having a low to moderate metastatic potential. The use of agents which increase or decrease cad-11 expression or function is also provided, including such use for prepn. of medicaments for modulating differentiation or neoplastic transformation of cells. A method for assessing the metastatic potential of carcinoma cells is also provided.

=> d 1 3-5

L4 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
 AN 2003192279 MEDLINE
 DN 22597384 PubMed ID: 12710956
 TI **Cadherin-11** modulates the terminal differentiation and fusion of human trophoblastic cells in vitro.
 AU Getsios Spiro; MacCalman Colin D
 CS Department of Obstetrics and Gynaecology, University of British Columbia, V5Z 4H4, Vancouver, B.C., Canada.
 SO DEVELOPMENTAL BIOLOGY, (2003 May 1) 257 (1) 41-54.
 Journal code: 0372762. ISSN: 0012-1606.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200306
 ED Entered STN: 20030425
 Last Updated on STN: 20030604
 Entered Medline: 20030603

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:185598 CAPLUS
 DN 134:217191
 TI Methods and compositions for treatment of inflammatory joint disease using **cadherin-11** modulating agents
 IN Brenner, Michael B.; Valencia, Xavier
 PA The Brigham and Women's Hospital, Inc., USA
 SO PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017557	A1	20010315	WO 2000-US24101	20000901
	WO 2001017557	C2	20020912		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1207905	A1	20020529	EP 2000-964937	20000901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI	US 1999-152456P	P	19990903		
	US 1999-153490P	P	19990913		
	WO 2000-US24101	W	20000901		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 2
AN 2001196503 MEDLINE
DN 21125871 PubMed ID: 11108717
TI In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by **cadherin-11**.
AU Orlandini M; Oliviero S
CS Dipartimento di Biologia Molecolare, Universita degli Studi di Siena via Fiorentina 1, 53100 Siena, Italy.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2001 Mar 2) 276 (9) 6576-81.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-D21253; GENBANK-D31963
EM 200104
ED Entered STN: 20010410
Last Updated on STN: 20030105
Entered Medline: 20010405

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:314717 CAPLUS
DN 132:329950
TI **Cadherin-11** expression and an assay and treatment for cellular invasiveness
IN MacCalman, Colin D.
PA The University of British Columbia, Can.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000026236	A2	20000511	WO 1999-CA1057	19991029
	WO 2000026236	A3	20000831		
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1144451	A2	20011017	EP 1999-953494	19991029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002528110	T2	20020903	JP 2000-579623	19991029
PRAI	US 1998-106258P	P	19981030		
	WO 1999-CA1057	W	19991029		